Recent studies have established that amplification of the MET proto-oncogene can cause resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) cell lines with EGFR-activating mutations. The role of nonamplified MET in EGFR-dependent signaling before TKI resistance, however, is not well understood. Using NSCLC cell lines and transgenic models, we demonstrate here that EGFR activation by either mutation or ligand binding increases MET gene expression and protein levels. Our analysis of 202 NSCLC patient specimens was consistent with these observations: levels of MET were significantly higher in NSCLC with EGFR mutations than in NSCLC with wild-type EGFR. EGFR regulation of MET levels in cell lines occurred through the hypoxiainducible factor (HIF)-1a pathway in a hypoxia-independent manner. This regulation was lost, however, after MET gene amplification or overexpression of a constitutively active form of HIF-1a. EGFR-and hypoxia-induced invasiveness of NSCLC cells, but not cell survival, were found to be MET dependent. These findings establish that, absent MET amplification, EGFR signaling can regulate MET levels through HIF-1a and that MET is a key downstream mediator of EGFR-induced invasiveness in EGFR-dependent NSCLC cells.
Introduction
Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the United States. Epidermal growth factor receptor (EGFR)-activating mutations have been described in a subset of NSCLC patients, and activated EGFR is known to influence tumor cell survival, proliferation, angiogenesis, and invasiveness (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004; Janne et al., 2005; Pao and Miller, 2005; Ciardiello and Tortora, 2008) . EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib are clinically active in 10-20% of NSCLC patients (Fukuoka et al., 2003; Kris et al., 2003; Shepherd et al., 2005; Thatcher et al., 2005) . Activating mutations within the EGFR tyrosine kinase domain including an amino acid substitution at exon 21 (L858R) and in-frame deletions in exon 19 were found to be predictors of clinical response to EGFR TKIs (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004) .
Recent evidence suggests that in NSCLC cells activating EGFR mutations or amplification of the MET proto-oncogene caused acquired resistance to EGFR TKIs by driving activation of the PI3K pathway (Engelman et al., 2007) . The role of MET in EGFRdependent signaling before the emergence of TKI resistance is not well understood; however, MET is regulated by hypoxia and hypoxia-inducible factor-1a and is thought to contribute to invasive tumor growth (Pennacchietti et al., 2003) . The MET protein is a receptor tyrosine kinases whose activation can cause malignant transformation and tumorigenesis (Cooper et al., 1986; Park et al., 1987; Stabile et al., 2004) . Upon ligand binding, MET activates downstream signaling molecules including PI3K, Src, and signal transducer and activator of transcription-3 (Rosario and Birchmeier, 2003) , triggering the key metastatic steps of cell dissociation (Qiao et al., 2002) , migration (Yi et al., 1998) , and invasion (Bredin et al., 2003) . MET is overexpressed in multiple malignancies and is associated with aggressive disease (Peruzzi and Bottaro, 2006) . In NSCLC, MET levels are elevated in resected tumors compared with normal tissue (Liu and Tsao, 1993; Ichimura et al., 1996; Olivero et al., 1996) , and high expression of the MET ligand hepatocyte growth factor (HGF) is associated with aggressive disease and a poor prognosis (Siegfried et al., 1998) .
Recent studies have suggested a link between EGFR signaling and MET. Expression and phosphorylation of EGFR and MET correlate in multiple malignancies (Weinberger et al., 2005) . Aberrant EGFR activation results in elevated MET phosphorylation in thyroid carcinoma cells (Bergstrom et al., 2000) . EGFR function has been implicated in HGF-induced hepatocyte proliferation (Scheving et al., 2002) and is required for MET-mediated colon cancer cell invasiveness (Pai et al., 2003) . Recent studies of phosphoprotein networks reveal an association between EGFR and MET activation (Huang et al., 2007; Guo et al., 2008) , and have reported direct crosstalk between EGFR and the MET (Jo et al., 2000; Huang et al., 2007) .
A plausible link between the EGFR and MET pathways is HIF-1, which has two subunits (HIF-1a and HIF-1b), and is known to contribute to tumor cell motility and invasiveness. EGF has been shown to modulate HIF-1a levels in prostate, breast, and lung cancer cell lines (Zhong et al., 2000; Phillips et al., 2005; Peng et al., 2006) , and positive correlations between EGFR and HIF-1a expression have been observed in NSCLC (Hirami et al., 2004; Swinson et al., 2004) .
Here, we have used clinical specimens, transgenic mouse models, and cell lines to investigate the hypothesis that EGFR signaling may regulate MET levels through HIF-1a but that MET amplification, which occurs in EGFR TKI resistance, would uncouple MET levels from EGFR regulation. We hypothesized further that EGFR-induced invasiveness, like hypoxia-induced invasiveness, is mediated downstream at least in part by the HIF-1a/MET axis.
Results

EGFR-activating mutations are associated with elevated levels of MET in NSCLC clinical samples
To investigate a possible association between EGFR activation and MET in clinical specimens, we evaluated MET levels by immunohistochemistry and assessed EGFR mutations in 202 human NSCLC clinical specimens. Out of 202 samples, 22 had detectable EGFR mutations. Specimens were immunostained for MET and scored based on an intensity score (0, 1, 2, or 3) and an extension percentage. The final score was the product of these two values. The mean score for MET expression was 39.46 ± 64.52. Therefore, a score of 40 was considered the cutoff for classifying low and high levels of MET expression. The mean MET expression score was significantly higher in specimens with mutated EGFR (73.64±70.68) than in specimens with WT EGFR (48.72±71.72; P ¼ 0.04; Figure 1a) . Furthermore, 37% of NSCLC tumors with WT EGFR expressed high levels of membranous MET, whereas 68% of NSCLC tumors with mutated EGFR expressed high levels of membranous MET (P ¼ 0.005; Figure 1b ). Among adenocarcinomas with EGFR-activating mutations, we did not observe any association between EGFR expression and survival. However, considering the small sample size, no definitive conclusions can be drawn.
EGFR activation modulates MET expression in transgenic murine models of NSCLC We investigated whether a similar association between EGFR-activating mutations and MET expression occurred in murine models of NSCLC. We used transgenic mice with lung tumors driven by lungspecific mutated K-RAS or activating EGFR mutation (Forsythe et al., 1996; Johnson et al., 2001) . Lung tumor sections were immunostained for MET and scored as described above. K-RAS-driven lesions had an average score of 6.75, whereas tumors with EGFRactivating mutations had an average staining score of 40.65 (Figure 1c ; Po0.001). Treatment of mice bearing EGFR-driven lung tumors with the EGFR TKI erlotinib (50 mg/kg/day) for 48 h abolished MET, providing evidence that MET levels were regulated by EGFR activation.
EGFR-activating mutations are associated with elevated HIF-1a and MET levels in NSCLC cell lines Given our finding that tumors with EGFR mutations exhibit higher MET expression, we investigated MET regulation by EGFR and its role in EGFR-mediated NSCLC invasiveness. We evaluated MET RNA levels in NSCLC cell lines by performing gene expression analysis on gene arrays of 53 previously characterized NSCLC lines (eight lines with mutated EGFR) (GEO 4824) . MET RNA levels were significantly higher in EGFR-mutated cell lines than in NSCLC cell lines expressing WT EGFR (Figure 2a ; P ¼ 0.002); however, MET expression levels in cell lines with K-RAS mutations were not significantly different compared with cell lines with WT K-RAS. Moreover, we observed a significant association between EGFR gene copy number (44 copies using RT-PCR) and levels of MET expression (P ¼ 0.03, Figure 2b ).
We evaluated MET protein levels in NSCLC with or without EGFR-activating mutations and observed constitutive EGFR phosphorylation in cell lines with mutated EGFR, which was associated with increased phosphorylated MET (p-MET) and MET expression (Figure 2c ). Cell lines with EGFR-activating mutations were positive for HIF-1a expression in normoxia. HCC827 cells, which exhibited the most robust expression of p-EGFR, produced the highest levels of HIF-1a, p-MET, and MET. Western data are supported by ELISA analysis showing higher levels of p-EGFR, p-MET, and HIF-1a in cell lines with EGFR-activating mutations compared with cells with WT EGFR (Figures 2d-f) .
Activated EGFR modulates p-MET, MET, and HIF-1a
We treated HCC827 cells with 1 mM of erlotinib for 12 h and evaluated p-MET, MET, and HIF-1a levels. Erlotinib reduced p-MET and MET protein (Figure 3a) . EGFR inhibition resulted in diminished HIF-1a levels. p-MET, MET, and p-EGFR were further analyzed by ELISA assay (Figure 3b ). Consistant with data obtained by western blot, erlotinib decreased p-EGFR (P ¼ 0.009), p-MET (P ¼ 0.1), and MET (P ¼ 0.001) levels. As HIF-1a is known to regulate MET transcription, we determined whether mutated EGFR would regulate MET mRNA levels. We treated HCC827 cells with or without erlotinib (1 mM) for 12 h and collected RNA for RT-PCR to evaluate changes in MET mRNA relative to GAPDH RNA. Inhibition of EGFR activity resulted in approximately a 50% decrease in MET RNA compared with control levels (Figure 3c ).
To further show that EGFR signaling modulates HIF-1a and MET protein expression, we transfected HCC827 cells with control siRNA and EGFR-, HIF-1a-, and MET-targeting siRNA. Knockdown of EGFR decreased p-MET, MET, and HIF-1a levels. HIF-1a-targeting siRNA did not alter EGFR expression but reduced MET expression and activation, whereas MET Activated EGFR regulates MET through HIF-1a L Xu et al siRNA reduced MET but not EGFR or HIF-1a levels ( Figure 3d ), indicating that HIF-1a and MET are downstream of EGFR. Similar results were obtained by HIF-1a ELISA assay. siRNA directed against EGFR but not MET decreased HIF-1a levels (P ¼ 0.009; Figure 3e ). MET amplification has been described in a subset of NSCLC patients (Zhao et al., 2005; Engelman et al., 2007) . To determine whether MET amplification would result in MET expression that was independent of EGFR, we treated H1993 NSCLC cells, which harbor an amplified MET allele (Engelman et al., 2007; Lutterbach et al., 2007) , with erlotinib, and evaluated p-EGFR, EGFR, p-MET and MET levels. In contrast to the EGFR-dependent cell lines tested, pharmacological inhibition of EGFR did not diminish MET expression in this cell line (Figure 3f ).
Previous studies suggested that activated EGFR can directly induce phosphorylation of MET (Bergstrom et al., 2000; Jo et al., 2000) . To evaluate the effect of EGFR activation on MET in NSCLC, we stimulated A549 cells with EGF with or without erlotinib. Phosphorylated EGFR was detected 30 min after ligand stimulation, and EGFR activation was inhibited with erlotinib ( Figure 3g ). EGFR levels decreased 12 h after the addition of EGF, which may have been a result of receptor internalization. EGF stimulation triggered rises in p-MET levels at 30 min, suggesting that EGFR directly activated MET. p-MET levels remained detectable 6 h after EGF stimulation. Prolonged exposure (24 h) to EGF resulted in increased levels of MET protein ( Figure 3h ).
EGFR-mediated invasion of NSCLC cells is MET dependent
To show that MET activation increases invasiveness in NSCLC and that this can be abrogated with the MET TKI, PHA-665752, we treated A549 and HCC827 tumor cells with the MET ligand HGF alone or with PHA-66752. Cell invasion was measured using Matrigelcoated Boyden chambers. In both cell lines, HGF stimulation resulted in a significant increase in invasiveness, and this was inhibited with the addition of PHA-665752 (Po0.05; Figure 4a ). As EGFR activation has been shown to modulate tumor cell invasion in multiple Activated EGFR regulates MET through HIF-1a L Xu et al cell types including NSCLC (Hamada et al., 1995; Damstrup et al., 1998) , we investigated whether EGFR activation's effect on tumor cell invasion is MET mediated. We stimulated A549 cells with EGF alone or with erlotinib or the MET TKI, PHA-665752. EGF induced a twofold increase in cell invasion compared with control (Po0.05; Figure 4b ). The addition of erlotinib or PHA-665752 reduced the number of invading cells to control levels, indicating that EGFRdriven cell invasion is MET dependent. In a similar experiment using HCC827 cells, in which EGFR is constitutively activated, EGF stimulation did not increase tumor cell invasiveness compared with control levels; however, pharmacological inhibition of EGFR or MET activation significantly reduced the number of invading cells (Figure 4c ; Po0.05).
To further elucidate the mechanism by which EGFR-activating mutations drive tumor cell invasion, we transfected HCC827 cells with EGFR-, HIF-1a-, or MET-targeting siRNA and evaluated cell invasion. Knockdown of EGFR, HIF-1a, or MET resulted in decreased invasive capacity (Figure 4d ; Po0.001), 
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L Xu et al whereas control siRNA did not affect invasive capacity. To confirm that decreases in the number of invasive cells after erlotinib or siRNA treatment was indeed do to changes in the invasive capacity of tumor cells and not because of changes in cell viability or proliferation, we separately performed a similar study in which the number of invasive cells was normalized to the number of cells that did not invade through the chamber (Supplemental Figure 1) . These data were in agreement with the findings shown above.
To determine whether MET inhibition impacted cellular growth, we conducted MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) assays in the presence of increasing concentrations of erlotinib or PHA-665752. HCC827 cells were sensitive to the EGFR inhibitor erlotinib (IC 50 o10 nM), whereas H1993 and A549 cells were less sensitive (Supplemental Figure 2) . None of the three cell lines were sensitive to PHA-665752 at concentrations as high as 10 mM. This suggested that invasiveness but not cell survival was MET dependent in these cell lines.
Hypoxia-induced invasiveness of NSCLC cells is MET dependent
Previous studies show that hypoxia increases the invasive capacity of tumor cells (Cuvier et al., 1997) . Therefore, we investigated whether MET activation mediates hypoxia-induced invasiveness of tumor cells. A549 cells were plated in Matrigel-coated Boyden chambers and incubated in normoxia (21% oxygen) or hypoxia (0.1% oxygen) with or without erlotinib or PHA-665752. Hypoxia enhanced tumor cell invasion more than 2.5-fold (Po0.001). Erlotinib caused a moderate decrease in tumor cell invasiveness, whereas MET inhibition reduced hypoxia-induced tumor cell invasion to levels below baseline (Figure 5a ; Po0.001).
To examine the role of HIF-1a in this pathway, we stably transfected A549 cells with a variant form of HIF-1a (HA-HIF-1a P402A;P564A) that is constitutively stabilized in normoxia because of proline to alanine substitutions at the VHL binding site critical for HIF-1a polyubiquitination and degradation (Masson et al., 2001; Hu et al., 2003; Kim et al., 2006) . Expression of the HIF-1a variant augmented MET production 
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( Figure 5b ) and was associated with enhanced tumor cell invasion (Po0.05; Figure 5c ). PHA-665752, but not erlotinib, reduced the number of invading cells to below baseline values (Po0.05). These findings were consistent with MET being a downstream mediator of HIF-1a-mediated invasiveness in thse cells. We examined the impact of WT and mutated EGFR, and the role of MET, on invasiveness in NIH-3T3 cells. NIH-3T3 cells were stably transfected with control GFP plasmid, WT EGFR or EGFR bearing the L858R mutation or the deletion mutant DL747-5752del. A greater than twofold increase in HIF-1a levels was observed in cells bearing the DL747-5752del deletion (P ¼ 0.02) or the L858R mutation (P ¼ 0.01) compared with GFP transfected controls (Figure 5d ). RT-PCR analysis revealed that NIH-3T3 cells expressing L858R expressed increased MET mRNA levels compared with GFP transfected controls (P ¼ 0.02; Figure 5e ). NIH-3T3 cells stably transfected with control GFP plasmid, WT EGFR, or EGFR bearing the L858R mutation or the deletion mutant DL747-5752del were allowed to invade Matrigel-coated Boyden chambers with or without PHA-66752. Cells expressing WT or activated EGFR had enhanced invasive capacity compared with cells transfected with GFP vector, and inhibition of MET significantly reduced the number of invasive cells to near baseline values (Figure 5f ).
Discussion
This study offers new insights into the mechanisms by which EGFR mediates its tumorigenic effects and provides new evidence that the HIF-1a/MET axis is critical to regulating invasiveness induced not only by hypoxia but by EGFR as well, thus illustrating the convergence of two pathways known to drive invasive Activated EGFR regulates MET through HIF-1a L Xu et al tumor growth. In NSCLC cells, we showed that EGFR activation, by either EGFR kinase mutations or ligand binding, increased MET levels through a hypoxiaindependent mechanism involving expression of HIF1a. MET was uncoupled from EGFR regulation, however, in a cell line with MET amplification, a finding consistent with the recently described role of MET amplification in EGFR TKI resistance (Engelman et al., 2007) . Overexpression of a constitutively active form of HIF-1a also abrogated the regulation of MET levels by EGFR. Therefore, though this study shows that EGFR signaling can regulate MET levels and that MET can be downstream mediator of EGFR-induced invasiveness, it also suggests that there are ways by which this pathway may be bypassed. We initially investigated MET levels in tumor specimens from 202 NSCLC patients by immunohistochemistry and observed increased levels of MET in tumors with EGFR-activating mutations compared with tumors with WT EGFR. Consistent with these findings, we observed elevated levels of MET in a previously described transgenic murine model of NSCLC with lung-specific expression of an EGFR-activating mutation. MET levels decreased significantly after treatment with the EGFR inhibitor erlotinib. We also observed that NSCLC cell lines expressing mutated EGFR exhibited elevated MET gene expression and protein levels compared with cells with WT EGFR, and these levels could be reduced by pharmacologically inhibiting EGFR or with siRNA directed against EGFR. The addition of an EGFR inhibitor decreased MET mRNA, indicating that in NSCLC cells, EGFR-activating mutations augment MET expression at the transcriptional level. Collectively, these results provide evidence that activated EGFR has a critical role in regulating MET expression in NSCLC tumor cells.
MET amplification has been described in the setting of gastric cancers (Smolen et al., 2006) and NSCLC (Engelman et al., 2007) . Engelman et al. (2007) reported that among lung cancers with EGFR-activating mutations, MET amplification occurred in 22% of tumors that developed resistance to gefitinib or erlotinib. Overall, MET amplification occurs in only 4% of all NSCLC cases (Zhao et al., 2005) , whereas high levels of MET and p-MET are detectable in 36 and 21% of NSCLC cases, respectively (Nakamura et al., 2007) . MET expression also has been shown to be regulated by hypoxia (Pennacchietti et al., 2003) . Here, we found evidence that EGFR is a key regulator of MET levels in cells without MET amplification, and that this occurs through hypoxiaindependent regulation of HIF-1a. By contrast, in H1993 cells bearing MET gene amplification, EGFR blockade did not result in a reduction in MET levels, suggesting that MET amplification resulted in an uncoupling of MET protein levels from EGFR regulation.
Ligand-induced phosphorylation of EGFR has been shown to induce rises in HIF-1a in a cell type-specific manner. We observed that HIF-1a levels were elevated in NSCLC cell lines bearing EGFR mutations even in the absence of added ligand, and that treatment with an EGFR inhibitor diminished HIF-1a expression.
Although this study did not specifically address the regulation of angiogenic factors such as VEGF, these findings are consistent with recent studies that EGFR regulates angiogenic factors, at least in part, through HIF-1a-dependent mechanisms (Swinson et al., 2004; Luwor et al., 2005; Pore et al., 2006; Swinson and O'Byrne, 2006) . Studies designed to elucidate the mechanism by which EGFR-activating mutations regulate HIF-1a levels are ongoing.
In addition to enhancing MET levels, EGFR activation resulted in increases in MET receptor phosphorylation within 30 min of EGF stimulation, an effect blocked by erlotinib. Similar observations have been made with other cell types (Bergstrom et al., 2000; Jo et al., 2000) ; these and other published data support the idea that EGFR may directly phosphorylate MET (Bergstrom et al., 2000; Jo et al., 2000) . Hypoxia is a known regulator of HGF, presumably through HIF-1a (Ide et al., 2006) . It is feasible that EGFR-activating mutations promote HGF production through HIF-1a. Collectively, these data suggest that EGFR/HIF-1a activation may not only regulate MET levels, but may also impact MET signal transduction through other mechanisms.
We investigated the consequences of EGFR-regulated MET. We observed that the invasiveness (Figure 4 ) but not survival (Supplemental Figure 2) of NSCLC cells bearing EGFR-activating mutations was MET dependent, as pharmacological inhibition or siRNA directed against MET abrogated cell invasion. Invasiveness and MET levels were reduced by siRNA knockdown of HIF-1a, whereas EGFR levels were unaffected; indicating that MET is downstream of HIF-1a and EGFR. We observed that EGF-and hypoxia-induced invasiveness were both MET dependent, and that heterologous expression of a constitutively active form of HIF-1a induced invasiveness that was independent of EGF stimulation but remained MET dependent ( Figure 5 ). Furthermore, heterologous expression of wild-type or mutated EGFR in NIH 3T3 fibroblasts increased invasiveness in an MET-dependent manner, providing further evidence that EGFR-mediated invasiveness is mediated at least in part by MET. These results support a model in which either hypoxia or EGFR activation can drive invasiveness by converging on a common HIF/MET pathway, which appears to be separable from EGFR-induced survival and proliferation. MET amplification appears to provide one route for circumventing this pathway. Others will likely emerge, and these findings do not exclude the likelihood that other pathways contribute to the invasive phenotype.
Our findings that EGFR can regulate MET levels through hypoxia-independent regulation of HIF-1a, and that MET is a downstream mediator of both EGFR-and hypoxia-induced invasivenss, have important clinical and biological implications. Even for tumors thought to be primarily driven by the EGFR pathway (that is with activating EGFR mutations), targeting of the MET pathway in combination with EGFR blockade may further reduce tumor invasiveness beyond the effect of EGFR inhibition alone, in addition to the previously noted potential benefit of preventing the emergence of resistance through MET amplification (Engelman et al., 2007) . It also raises the question of whether other tyrosine kinases may regulate MET in a similar manner in NSCLC and other diseases. Finally, the observation that the EGFR and hypoxia converge on the HIF-1a/MET axis suggests that there may be additional overlap in the mechanisms by which EGFR and hypoxia promote malignant behavior and therapeutic resistance.
Materials and methods
Cell lines
Drs John Minna and Adi Gazdar (UT Southwestern Medical School, Dallas, TX, USA) provided H3255, H1975, H1993, and HCC827 cells. A549 and Calu-6 were obtained from the ATCC (Rockville, MD, USA). NIH-3T3 cells expressing WT EGFR or EGFR bearing the L858R mutation or the deletion mutant DL747-S752del (Shimamura et al., 2005) were obtained from Dr Jeffrey Engelman (Dana-Farber Cancer Institute) and were maintained in 10% FBS DMEM containing 1 mg/ml puromycin.
Mice
Animals were treated in accordance with the guidelines of the US Department of Agriculture and the NIH. Kras LA1 mice (Johnson et al., 2001) were obtained from Dr Tyler Jacks (Massachusetts Institute of Technology, Cambridge, MA, USA). CCSP-rtTA transgenic mice (obtained from J Whitsett at The University of Cincinnati, Cincinnati, OH, USA) were bred with Tet-op-hEGFR L858R-Luc to yield mice with lung tumors driven by EGFR activation (Ji et al., 2006) . At 6 months of age, lungs were collected. Animals bearing EGFRdriven lung tumors were treated with vehicle (1% Tween-80; Sigma-Aldrich, St Louis, MO, USA), or erlotinib (50 mg/kg/ day) by gavage for 48 h.
Gene expression analysis
Affymetrix GeneChip Human Genome U133A (HG-U133A) was used to perform gene expression analysis on 53 gene arrays of NSCLC cell lines prepared by John Minna and colleagues (UT Southwestern, Dallas, TX, USA; . CEL-type data files were obtained from NCBI-GEO dataset GSE4824 (NCBI-GEO, 2007) . CHIP (2007) software (http:// biosun1.harvard.edu/complab/dchip/) was used to generate probelevel gene expression, median intensity, percentage of probe set outliers, and percentage of single probe outliers (Lin et al., 2004) . Information files, including the HG-U133A gene information files and Chip Description Files, were downloaded from the Affymetrix web site. CEL and other data files were extracted. Array images were inspected for contamination and bad hybridization. Normalization was performed using the invariant-set normalization method (Li and Hung Wong, 2001) . Model-based expression and background subtraction using the 5th percentile of region (perfect match only) was completed by checking for single, array, and probe outliers. In the array analysis and clustering, array outliers were treated as missing values and no log transformation was performed. Comparison within dCHIP of the WT EGFR vs mutated EGFR groups using a more than 1.2-fold change in gene expression, a 90% confidence interval for fold change, and a 90% present call yielded one probeset for MET (203510_at). Data were further analyzed using GraphPad software (version 5, GraphPad Software Inc., La Jolla, CA, USA).
Detection of HIF-1a, MET, and EGFR Protein lysates were extracted using RIPA buffer (50mM TrisHCl, pH 7.4, 150mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, and 0.1% SDS, and protease inhibitors. Protein (60 mg) was used for western blotting. Antibodies against EGFR (Y1068, Cell Signaling Technology Inc., Danvers, MA, USA), EGFR (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) MET (Santa Cruz), HIF-1a (Pharmingen, San Diego, CA, USA), b-actin (Sigma), and vinculin (Sigma) were used. HIF-1a, p-EGFR, MET, and p-MET ELISAs were obtained from R&D systems (Minneapolis, MN, USA).
RNA isolation and RT-PCR HCC827 cells were treated with complete media with or without 1 mM erlotinib for 12 h. Total RNA was extracted using Trizol (Life Technologies, Carlsbad, CA, USA), and purified with the RNeasy kit (Qiagen, Hilden, Germany). We used SuperScriptTM III RNase H-Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) to convert RNA into cDNA. The oligonucleotide primers used were published previously (Shimazaki et al., 2003) .
Plasmids and transfections HIF-1a cDNA (OriGene Technologies Inc., Rockville, MD, USA) was subcloned into the pcDNA3.1 vector with a flag tagged in the N-terminal, and the HIF-1a mutant with proline to alanine substitutions positions 402 and 564 (HA-HIF-1a P402A;P564A), which are known VHL-binding sites, was constructed as described (Kim et al., 2006) . This form is stabilized in normoxia because of the loss of VHL-mediated polyubiquitination and subsequent degradation (Masson et al., 2001; Hu et al., 2003) . For siRNA transfections, HCC827 cells were transfected with siRNA targetting EGFR, MET, HIF-1a and control siRNA at a final concentration of 100 nM using Dharmafect 1 transfection reagent (Dharmacon, Lafayette, CO, USA). Protein was isoloated after 72 h. Transfected cells were plated for invasion assays after 48 h.
Invasion assay
We seeded 2.5 Â 10 4 cells in the upper chamber of 24-well BD Biocoat growth factor reduced Matrigel invasion chambers (8.0 mm pore, Becton Dickinson, Bedford, MA, USA) with 0% FBS media and added media containing 10% FBS to the lower chamber. After 24 h, cells in the upper chamber were removed by scraping. Cells that migrated to the lower chamber were stained and counted using bright-field microscopy under a low-power ( Â 40) objective. PHA-663225 was obtained from Pfizer (New York, NY, USA).
Clinical specimens
Tissue specimens from 202 surgically resected lung carcinomas were obtained from the Lung Cancer Specialized Program of Research Excellence (SPORE) Tissue Bank at The University of Texas MD Anderson Cancer Center (Houston, TX, USA). Two hundred and two specimens had known EGFR status. Microarrays for each specimen were created with three cores from formalin-fixed, paraffin-embedded blocks. All specimens were of pathologic TNM stages I-IV according to the revised International System for Staging Lung Cancer (Beadsmoore and Screaton, 2003) .
Immunohistochemistry staining
Using paraffin-embedded tissue sections, antigen retrieval was performed by steaming in citrate buffer (pH 6.0). Endogenous peroxidases were blocked using 3% H 2 O 2 . After protein blocking, slides were incubated with anti-HGFR (1:50; R&D Systems), washed, and incubated with a Universal LSAB þ Kit/HRP, visualization kit (DakoCytomation, Carpinteria, CA, USA). For tumor sections from transgenic animals, antigen retrieval and blocking was performed as above. Slides were incubated in 1:100 anti-mouse MET antibodies (Santa Cruz) and then in secondary antibody (Jackson Research Laboratories, Bar Harbor, ME, USA). NSCLC specimens were used as positive controls for MET staining. As a negative control, we followed the above procedure omitting the primary antibodies. For quantification, each specimen was evaluated using an intensity score (0, 1, 2, or 3) and an extension percentage (Yang et al., 2008) . The final staining score was the product of these two values. An average from the three cores was obtained for each specimen.
Statistics
Student's t-tests were performed using two-tailed tests with unequal variance for Gaussian distributed data. For statistical analysis of clinical specimens, Wilcoxon rank-sum tests were used when comparing continuous variables between mutation groups. To correlate mutation and other discrete covariates, we used a chi-square test or Fisher's exact test. Two-sided P-values p0.05 were considered significant.
Accession numbers SNP and CGH raw data are available in the Gene Expression Omnibus (GEO) database: GEO accession GSE4824 (http:// www.ncbi.nlm.nih.gov/geo/).
